Morgan Stanley Annovis Bio, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 7,156 shares of ANVS stock, worth $39,787. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,156

Previous 1,434 399.02%

Holding current value

$39,787

Previous $26,000 226.92%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.47 - $18.93 $48,465 - $108,317	5,722 Added 399.02%	7,156 $85,000
Q3 2023 Nov 15, 2023	BUY	$9.37 - $14.12 $206 - $310	22 Added 1.56%	1,434 $13,000
Q2 2023 Aug 14, 2023	SELL	$11.95 - $16.31 $3,453 - $4,713	-289 Reduced 16.99%	1,412 $20,000
Q1 2023 May 15, 2023	SELL	$12.33 - $22.1 $344,685 - $617,805	-27,955 Reduced 94.26%	1,701 $26,000
Q4 2022 Feb 14, 2023	SELL	$10.99 - $13.55 $127,824 - $157,600	-11,631 Reduced 28.17%	29,656 $398,000

Q3 2022 Nov 14, 2022	SELL	$10.26 - $21.81 $152,371 - $323,900	-14,851 Reduced 26.45%	41,287 $566,000
Q2 2022 Oct 27, 2022	SELL	$8.61 - $13.87 $464,251 - $747,870	-53,920 Reduced 48.99%	56,138 $636,000
Q2 2022 Aug 15, 2022	SELL	$8.61 - $13.87 $464,251 - $747,870	-53,920 Reduced 48.99%	56,138 $636,000
Q1 2022 Oct 27, 2022	BUY	$11.84 - $19.78 $638,412 - $1.07 Million	53,920 Added 96.05%	110,058 $1.47 Million
Q1 2022 May 13, 2022	SELL	$11.84 - $19.78 $531,888 - $888,576	-44,923 Reduced 28.99%	110,058 $1.47 Million
Q4 2021 Feb 14, 2022	BUY	$17.58 - $37.67 $2.06 Million - $4.41 Million	117,015 Added 308.21%	154,981 $2.72 Million
Q3 2021 Nov 15, 2021	BUY	$30.95 - $120.97 $1.18 Million - $4.59 Million	37,966 New	37,966 $1.21 Million

Others Institutions Holding ANVS

# of Institutions

Shares Held

1.2M

Call Options Held

779K

Put Options Held

1.77M

View Full List

About Annovis Bio, Inc.

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $45.4M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

More about ANVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account